Neurocrine Biosciences Statistics
Share Statistics
Neurocrine Biosciences has 101.25M shares outstanding. The number of shares has increased by 1.75% in one year.
| Shares Outstanding | 101.25M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.27% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 98.54M |
| Failed to Deliver (FTD) Shares | 143 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.39M, so 3.35% of the outstanding shares have been sold short.
| Short Interest | 3.39M |
| Short % of Shares Out | 3.35% |
| Short % of Float | 3.44% |
| Short Ratio (days to cover) | 3.86 |
Valuation Ratios
The PE ratio is 51.55 and the forward PE ratio is 20.45. Neurocrine Biosciences 's PEG ratio is 0.14.
| PE Ratio | 51.55 |
| Forward PE | 20.45 |
| PS Ratio | 6.82 |
| Forward PS | 4.4 |
| PB Ratio | 5.77 |
| P/FCF Ratio | 35.6 |
| PEG Ratio | 0.14 |
Enterprise Valuation
Neurocrine Biosciences Inc. has an Enterprise Value (EV) of 13.05B.
| EV / Earnings | 52.26 |
| EV / Sales | 6.92 |
| EV / EBITDA | 36.45 |
| EV / EBIT | 52.01 |
| EV / FCF | 36.09 |
Financial Position
The company has a current ratio of 2.45, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.45 |
| Quick Ratio | 2.4 |
| Debt / Equity | 0.08 |
| Total Debt / Capitalization | 7.08 |
| Cash Flow / Debt | 2.29 |
| Interest Coverage | 54.54 |
Financial Efficiency
Return on equity (ROE) is 0.11% and return on capital (ROIC) is 7.09%.
| Return on Equity (ROE) | 0.11% |
| Return on Assets (ROA) | 0.08% |
| Return on Capital (ROIC) | 7.09% |
| Revenue Per Employee | 1.11M |
| Profits Per Employee | 146.88K |
| Employee Count | 1.70K |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.04 |
Taxes
| Income Tax | 82.40M |
| Effective Tax Rate | 0.25 |
Stock Price Statistics
The stock price has increased by 5.18% in the last 52 weeks. The beta is 0.35, so Neurocrine Biosciences 's price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | 5.18% |
| 50-Day Moving Average | 129.71 |
| 200-Day Moving Average | 132.9 |
| Relative Strength Index (RSI) | 60.83 |
| Average Volume (20 Days) | 987.60K |
Income Statement
In the last 12 months, Neurocrine Biosciences had revenue of 1.89B and earned 249.70M in profits. Earnings per share was 2.56.
| Revenue | 1.89B |
| Gross Profit | 1.85B |
| Operating Income | 250.90M |
| Net Income | 249.70M |
| EBITDA | 358.00M |
| EBIT | 250.90M |
| Earnings Per Share (EPS) | 2.56 |
Balance Sheet
The company has 251.10M in cash and 428.40M in debt, giving a net cash position of -177.30M.
| Cash & Cash Equivalents | 251.10M |
| Total Debt | 428.40M |
| Net Cash | -177.30M |
| Retained Earnings | -157.10M |
| Total Assets | 3.54B |
| Working Capital | 1.45B |
Cash Flow
In the last 12 months, operating cash flow was 389.90M and capital expenditures -28.30M, giving a free cash flow of 361.60M.
| Operating Cash Flow | 389.90M |
| Capital Expenditures | -28.30M |
| Free Cash Flow | 361.60M |
| FCF Per Share | 3.7 |
Margins
Gross margin is 97.9%, with operating and profit margins of 13.3% and 13.23%.
| Gross Margin | 97.9% |
| Operating Margin | 13.3% |
| Pretax Margin | 17.6% |
| Profit Margin | 13.23% |
| EBITDA Margin | 18.97% |
| EBIT Margin | 13.3% |
| FCF Margin | 19.16% |
Dividends & Yields
NBIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.84% |
| FCF Yield | 2.56% |
Analyst Forecast
The average price target for NBIX is $164, which is 17.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $164 |
| Price Target Difference | 17.6% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
Scores
| Altman Z-Score | 12.04 |
| Piotroski F-Score | 6 |